Issue 67, 2016

Urine metabolic phenotypes analysis of extrahepatic cholangiocarcinoma disease using ultra-high performance liquid chromatography-mass spectrometry

Abstract

Extrahepatic cholangiocarcinoma (ECC) is the second most common type of malignant primary tumor with a poor survival rate and an increasing global trend. However, the metabolic phenotype characteristics of ECC have not been explored. Metabolomics has shown significant potential in identifying small molecules specific to disease phenotypes. In this study, liquid chromatography-mass spectrometry (LC/MS) in combination with multivariate statistical analysis was conducted to explore the urine metabolic changes of ECC. An untargeted metabolomics assay was conducted on urine samples of ECC patients and healthy controls. Multivariate pattern recognition analysis was used to reduce the high dimensionality of the metabolome dataset, differentiating between the ECC patients and healthy subjects. Score plots of the spectra revealed the separation between the ECC cases and controls for the level of metabolites. A total of 19 differential metabolites were identified and contributed to ECC. In the pathway analysis, a total of 29 significant metabolic pathways were identified. All the metabolic perturbations in the ECC disease status are associated with three key pathways, including pyruvate metabolism and citrate cycle, and these metabolic pathways may provide a potentially new target for diagnosis and therapy. Of note, network analysis found that abnormally expressed metabolites were tightly correlated with the metabolism pathway. The identified differential metabolites and metabolic pathways responsible for ECC were all imported into a web tool for network-based interpretation of compound lists to interpret their functional context, molecular mechanisms and disturbed pathways. Overall, it demonstrated that clinical metabolomics may highlight biomarkers and pathways and can capture subtle metabolic phenotype changes from ECC, which may lead to an improved mechanistic understanding of ECC.

Graphical abstract: Urine metabolic phenotypes analysis of extrahepatic cholangiocarcinoma disease using ultra-high performance liquid chromatography-mass spectrometry

Supplementary files

Article information

Article type
Communication
Submitted
12 Apr 2016
Accepted
01 Jun 2016
First published
02 Jun 2016

RSC Adv., 2016,6, 63049-63057

Urine metabolic phenotypes analysis of extrahepatic cholangiocarcinoma disease using ultra-high performance liquid chromatography-mass spectrometry

X. Wang, J. Li and A. Zhang, RSC Adv., 2016, 6, 63049 DOI: 10.1039/C6RA09430A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements